GRAIL, Inc. Common Stock
GRAL Real Time Price USDRecent trades of GRAL by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in GRAL holdings by institutional investors
Quarterly net insider trading by GRAL's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$50,000 Oct 20, 2025 Issue: Health Issues Medicare/Medicaid
-
$20,000 Oct 20, 2025 Issue: Health Issues Medicare/Medicaid
-
$600,000 Oct 20, 2025 Issue: Medicare/Medicaid Health Issues
-
$60,000 Oct 20, 2025 Issue: Medicare/Medicaid
-
$50,000 Oct 20, 2025 Issue: Medicare/Medicaid
-
$20,000 Oct 20, 2025 Issue: Health Issues Medicare/Medicaid
-
$50,000 Oct 19, 2025 Issue: Health Issues Medicare/Medicaid
-
$30,000 Oct 18, 2025 Issue: Health Issues Medicare/Medicaid
-
$30,000 Oct 09, 2025 Issue: Health Issues
-
$20,000 Jul 21, 2025 Issue: Health Issues Medicare/Medicaid
-
$580,000 Jul 21, 2025 Issue: Health Issues Medicare/Medicaid
-
$50,000 Jul 21, 2025 Issue: Medicare/Medicaid Health Issues
-
$50,000 Jul 21, 2025 Issue: Medicare/Medicaid
-
$30,000 Jul 21, 2025 Issue: Health Issues Medicare/Medicaid
-
$20,000 Jul 21, 2025 Issue: Health Issues Medicare/Medicaid
-
$60,000 Jul 21, 2025 Issue: Medicare/Medicaid
-
$50,000 Jul 18, 2025 Issue: Health Issues Medicare/Medicaid
-
$30,000 Jul 15, 2025 Issue: Health Issues
-
$500,000 May 05, 2025 Issue: Health Issues Medicare/Medicaid
-
$50,000 Apr 21, 2025 Issue: Medicare/Medicaid
-
$50,000 Apr 21, 2025 Issue: Medicare/Medicaid Health Issues
-
$20,000 Apr 21, 2025 Issue: Health Issues Medicare/Medicaid
-
$20,000 Apr 21, 2025 Issue: Health Issues Medicare/Medicaid
-
$20,000 Apr 21, 2025 Issue: Medicare/Medicaid
-
$30,000 Apr 20, 2025 Issue: Health Issues Medicare/Medicaid
-
$30,000 Apr 17, 2025 Issue: Health Issues
-
$50,000 Apr 15, 2025 Issue: Health Issues Medicare/Medicaid
-
$30,000 Jan 21, 2025 Issue: Health Issues Medicare/Medicaid
-
$20,000 Jan 21, 2025 Issue: Health Issues Medicare/Medicaid
-
$50,000 Jan 21, 2025 Issue: Medicare/Medicaid
-
$650,000 Jan 21, 2025 Issue: Health Issues Medicare/Medicaid
-
$50,000 Jan 21, 2025 Issue: Health Issues Medicare/Medicaid
-
$50,000 Jan 21, 2025 Issue: Medicare/Medicaid
-
$30,000 Jan 20, 2025 Issue: Health Issues
-
$50,000 Jan 17, 2025 Issue: Health Issues Medicare/Medicaid
-
$30,000 Oct 21, 2024 Issue: Medicare/Medicaid Health Issues
-
$50,000 Oct 21, 2024 Issue: Medicare/Medicaid
-
$540,000 Oct 21, 2024 Issue: Medicare/Medicaid Health Issues
-
$50,000 Oct 21, 2024 Issue: Medicare/Medicaid
-
$50,000 Oct 21, 2024 Issue: Medicare/Medicaid Health Issues
-
$30,000 Oct 21, 2024 Issue: Medicare/Medicaid Health Issues
-
$30,000 Oct 18, 2024 Issue: Health Issues
-
$50,000 Oct 17, 2024 Issue: Medicare/Medicaid Health Issues
-
$30,000 Jul 22, 2024 Issue: Medicare/Medicaid Health Issues
-
$50,000 Jul 22, 2024 Issue: Medicare/Medicaid
-
$30,000 Jul 22, 2024 Issue: Medicare/Medicaid Health Issues
-
$50,000 Jul 22, 2024 Issue: Medicare/Medicaid Health Issues
GRAL Estimated quarterly lobbying spending
GRAL Revenue by Segment or Geography
New GRAL patent grants
-
Patent Title: Methods for analyzing viral nucleic acid Nov. 04, 2025
-
Patent Title: Methylation markers and targeted methylation probe panel Oct. 07, 2025
-
Patent Title: Methylation markers and targeted methylation probe panel Sep. 09, 2025
-
Patent Title: Enrichment of short nucleic acid fragments in sequencing library preparation Aug. 12, 2025
-
Patent Title: Convolutional neural network systems and methods for data classification Aug. 05, 2025
-
Patent Title: Methods of preparing dual-indexed dna libraries for bisulfite conversion sequencing Apr. 01, 2025
-
Patent Title: Detecting cross-contamination in sequencing data Feb. 25, 2025
-
Patent Title: Systems and methods for using a convolutional neural network to detect contamination Feb. 25, 2025
-
Patent Title: Source of origin deconvolution based on methylation fragments in cell-free dna samples Feb. 25, 2025
-
Patent Title: Systems and methods for classifying patients with respect to multiple cancer classes Jan. 07, 2025
-
Patent Title: Base coverage normalization and use thereof in detecting copy number variation Sep. 24, 2024
-
Patent Title: Dynamically selecting sequencing subregions for cancer classification Aug. 27, 2024
-
Patent Title: Methods and systems for screening for conditions Jul. 30, 2024
-
Patent Title: Anomalous fragment detection and classification Jul. 02, 2024
-
Patent Title: Methods of preparing and analyzing cell-free nucleic acid sequencing libraries Jul. 02, 2024
-
Patent Title: Methylation markers and targeted methylation probe panel Jul. 02, 2024
-
Patent Title: Detecting cross-contamination in sequencing data using regression techniques Jun. 11, 2024
-
Patent Title: Models for targeted sequencing Apr. 16, 2024
-
Patent Title: Systems and methods for enriching for cancer-derived fragments using fragment size Mar. 12, 2024
-
Patent Title: Methods for managing sequencing pileups Feb. 27, 2024
-
Patent Title: Tissue-specific methylation marker Jan. 30, 2024
-
Patent Title: Systems and methods for determining whether a subject has a cancer condition using transfer learning Jan. 09, 2024
-
Patent Title: Enrichment of short nucleic acid fragments in sequencing library preparation Dec. 26, 2023
-
Patent Title: Methylation markers and targeted methylation probe panel Oct. 24, 2023
-
Patent Title: Convolutional neural network systems and methods for data classification Oct. 10, 2023
-
Patent Title: Systems and methods for automated classification of a document Oct. 10, 2023
-
Patent Title: Methylation-based false positive duplicate marking reduction Oct. 03, 2023
-
Patent Title: Methods and systems for analyzing nucleic acid sequences using mappability analysis and de novo sequence assembly Aug. 15, 2023
-
Patent Title: Methylation markers and targeted methylation probe panel Aug. 15, 2023
-
Patent Title: Methylation markers and targeted methylation probe panel Jun. 27, 2023
-
Patent Title: Needle-based devices and methods for in vivo diagnostics of disease conditions Jun. 20, 2023
-
Patent Title: Enrichment of mutated cell free nucleic acids for cancer detection Apr. 11, 2023
-
Patent Title: Methods of analyzing nucleic acid fragments Mar. 14, 2023
-
Patent Title: Library preparation and use thereof for sequencing based error correction and/or variant identification Feb. 21, 2023
-
Patent Title: Systems and methods for classifying patients with respect to multiple cancer classes Feb. 14, 2023
-
Patent Title: Methods of preparing dual-indexed dna libraries for bisulfite conversion sequencing Jan. 31, 2023
-
Patent Title: Methods for detecting disease using analysis of rna Nov. 29, 2022
-
Patent Title: Convolutional neural network systems and methods for data classification Oct. 25, 2022
-
Patent Title: Alignment free filtering for identifying fusions Oct. 18, 2022
-
Patent Title: Nucleic acid rearrangement and integration analysis Sep. 20, 2022
-
Patent Title: Methods for enriching for duplex reads in sequencing and error correction Aug. 16, 2022
-
Patent Title: Methylation markers and targeted methylation probe panel Aug. 09, 2022
-
Patent Title: Enhanced ligation in sequencing library preparation Mar. 15, 2022
-
Patent Title: Differential tagging of rna for preparation of a cell-free dna/rna sequencing library Nov. 23, 2021
-
Patent Title: Higher target capture efficiency using probe extension Sep. 14, 2021
-
Patent Title: Methods for high efficiency library preparation using double-stranded adapters Apr. 20, 2021
-
Patent Title: Methods of preparing and analyzing cell-free nucleic acid sequencing libraries Feb. 02, 2021
-
Patent Title: Methods for single-stranded nucleic acid library preparation Nov. 03, 2020
-
Patent Title: Methods of preparing and analyzing cell-free nucleic acid sequencing libraries Nov. 26, 2019
-
Patent Title: Differential tagging of rna for preparation of a cell-free dna/rna sequencing library Dec. 04, 2018
Federal grants, loans, and purchases
Estimated quarterly amount awarded to GRAL from public contracts
Recent insights relating to GRAL
Recent picks made for GRAL stock on CNBC
ETFs with the largest estimated holdings in GRAL
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $GRAL stock a Buy, Sell, or Hold?
- What is the price target for $GRAL stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $GRAL stock?
- Who owns the most shares of $GRAL stock?
- What funds own $GRAL stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view GRAL Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.
- Address Menlo Park, CA
- Market Cap 3.6 billion
- Employees 1,000
- Industrial Classification Services-Medical Laboratories